From: Long Investing Ideas from Seeking Alpha - 8:49am - February 20, 2012By Steve Rosenman: Biotech stocks are synonymous with risk. So, it is always exciting to talk about a company with little to no risk hurdles in the way of therapeutic efficacy and patient safety. In short, Amarin's (AMRN) two highly successful phase III clinical trials (Anchor and Marine) pretty much turned AMRN stock certificates into winning lottery tickets. But, what is the jackpot paying? Amarin reached nearly $20 in 2011, only to decline to near pre-phase III levels over the past few months. Investors have been getting back into Amarin, pushing shares higher recently. What's next for Amarin and the lucky lottery winners that have invested in the company?If you have been following AMRN you probably understand the very near term opportunity to go against GlaxoSmithKline's (GSK) prescription drug Lovaza. What you may not understand (and clearly many investors do not, seeing th...
Continue reading this article ?
Source: http://ewallstreeter.com/what-s-next-for-amarin-s-lucky-investors-3738/
butterball turkey fryer yale harvard dan henderson oregon ducks oregon ducks oregon football lana turner
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.